

Joint Event

18th Annual Congress on
Pharmaceutics & Drug Delivery Systems | Diabetes & Nursing Care
June 27-28, 2019 | Amsterdam, Netherlands


KRAS mutation in advanced lung cancer: Response

Lung cancer is a malignant respiratory tumor with rapid development and poor prognosis. VATS(video-assisted thoracic surgery) is the main treatment for early lung cancer, but the majority of patients are diagnosed at stage IIIB or IV. Platinum-based chemotherapy regimen is currently considered key components of first-line chemotherapy for advanced lung cancer; however, there are no standard treatment plans for lung cancer with KRAS mutation. Apatinib has been successfully applied as third-line treatment for advanced gastric cancer and has shown high efficacy in the treatment of various cancer. Herein we report a case of advanced lung cancer harboring KRAS mutation in which apatinib was administered and a partial response was achieved after four months of treatment. To date, a 10 months of progression-free survival have been achieved. Adverse reactions can be controlled and the patient's quality of life has improved. Apatinib provides a new option for clinicians to treat patients with advanced KRAS-mutation lung cancer.

Biography

Yang Yuan has completed his master at the age of 27 years from Kunming Medical University. He is currently engaged in basic and clinical research of lung cancer. He has published more than 10 papers in journals around the world and has been serving as an oncology member of CSCO.

yangyuan_china@hotmail.com



Yang Yuan

Kunming Medical University, China

Co-Author

Ma Qianli

Yunnan Cancer Hospital, China